Navigation Links
Landmark studies assess risk of exposure to elevated levels of EMS confirm clear toxicity threshold
Date:8/4/2008

Basel, 4 August 2008. New data from studies presented at the XVII International AIDS Conference in Mexico City have provided unprecedented insight into the toxicity of an impurity called ethyl methanesulfonate (EMS). The formation of the EMS impurity is a potential by-product of the manufacturing of mesylate salts, which are contained in over 40 drugs currently available worldwide.

The studies were designed to determine the impact of elevated EMS levels in some batches of Roche's Viracept (nelfinavir mesylate) and demonstrated a clear threshold response at which DNA damage, the underlying mechanism for the carcinogenesis of EMS, occurs. The results of these animal studies, which can be translated to humans with high confidence, confirm that Viracept patients exposed to the EMS impurity at levels well below this threshold are not at an increased risk of cancer.

"These data provide unprecedented insight into the toxicity of EMS for humans. They will change the long held perceptions of the hazards posed by low doses of some genotoxic carcinogens", said Professor David Tweats, Department of Medicine and Genetics, University of Wales Swansea, UK.

EMS is a known DNA-damaging agent capable of inducing gene mutations and chromosomal aberrations. Although existing in vitro data indicated that there was a threshold response at lower doses of EMSi at which no DNA damage was observed, the total body of literature about EMS at low doses was limited. Consequently, available data did not permit an adequate risk assessment for patients exposed to EMS in Viracept. Roche -- in agreement with the European regulatory agency -- undertook the largest and most comprehensive toxicology evaluation of EMS to-date.

Scientists investigated the genetic toxicity of EMS using the following sets of studies:

  • Measurement of chromosomal damage in mice

  • Quantification of gene mutations in the transgenic MutaMouse model - the largest study of its kind ever conducted

  • Modelling of exposure and metabolism of EMS in humans based on experimental animal data

The first study clearly demonstrated a threshold-dose response with no chromosomal damage at EMS doses up to and including, 80 mg/kg/day. The second set of studies, the transgenic MutaMouse studies, also showed a clear threshold effect for mutations above 25 mg/kg/day, under chronic conditions. Effects were also shown not to be cumulative over time. This threshold is far above 0.055 mg/kg/day -- the highest estimated levels to which Viracept patients were exposed for no longer than 3-6 months.

The research team used these results to predict human exposure to EMS. They predicted that even at a maximal exposure level 370-fold higher than that calculated for affected Viracept patients, the damage potentially incurred by EMS can still effectively be dealt with by ubiquitous DNA repair mechanisms. As chromosome damage and mutations are the underlying molecular events for birth defects and cancer, the results of these studies can be used to reassure patients exposed to elevated levels of EMS, and their healthcare providers, that they are not at increased risk for developing cancer.


'/>"/>

Contact: Sbastien Desprez
sebastien.desprez@ketchum.com
44-077-682-38289
Ketchum
Source:Eurekalert

Related biology news :

1. Safeway Inc. and PCF to fund landmark prostate cancer research collaboration
2. SAGE and Hindawi announce landmark open access agreement
3. Claims of sex-related differences in genetic association studies often not properly validated
4. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
5. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
6. Studies: Children obese due to a host of unhealthy pressures
7. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
8. LSU professor studies army-ant-following birds
9. 2 carotid artery stenting studies show results comparable to AHA guidelines
10. NIH grants enable energy studies
11. New studies on schizophrenia, depression, trauma and autism highlight annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The ...
Breaking Biology Technology: